TG Therapeutics Inc (NASDAQ:TGTX) – Jefferies Group boosted their FY2018 earnings per share (EPS) estimates for TG Therapeutics in a research note issued on Tuesday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will earn ($1.62) per share for the year, up from their prior forecast of ($1.78). Jefferies Group also issued estimates for TG Therapeutics’ FY2019 earnings at ($1.94) EPS.

TGTX has been the subject of a number of other research reports. B. Riley started coverage on TG Therapeutics in a report on Friday, December 1st. They issued a “buy” rating and a $21.50 price target for the company. Zacks Investment Research lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a report on Monday, January 8th. BidaskClub lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 23rd. Finally, Raymond James Financial reiterated a “buy” rating on shares of TG Therapeutics in a report on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $25.50.

Shares of TG Therapeutics (NASDAQ:TGTX) traded up $0.85 during trading hours on Thursday, hitting $12.45. The company’s stock had a trading volume of 1,994,100 shares, compared to its average volume of 1,721,226. TG Therapeutics has a fifty-two week low of $4.50 and a fifty-two week high of $15.35. The stock has a market capitalization of $819.57, a price-to-earnings ratio of -6.45 and a beta of 1.67.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. lifted its holdings in TG Therapeutics by 22.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 87,950 shares of the biopharmaceutical company’s stock worth $884,000 after buying an additional 15,900 shares during the period. Legal & General Group Plc lifted its holdings in TG Therapeutics by 14.9% during the second quarter. Legal & General Group Plc now owns 11,264 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,463 shares during the period. Teachers Advisors LLC lifted its holdings in TG Therapeutics by 17.6% during the second quarter. Teachers Advisors LLC now owns 88,736 shares of the biopharmaceutical company’s stock worth $892,000 after buying an additional 13,304 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in TG Therapeutics by 65.2% during the second quarter. TIAA CREF Investment Management LLC now owns 165,741 shares of the biopharmaceutical company’s stock worth $1,666,000 after buying an additional 65,426 shares during the period. Finally, Ameriprise Financial Inc. lifted its holdings in TG Therapeutics by 150.2% during the second quarter. Ameriprise Financial Inc. now owns 277,235 shares of the biopharmaceutical company’s stock worth $2,786,000 after buying an additional 166,434 shares during the period. Hedge funds and other institutional investors own 47.44% of the company’s stock.

In related news, CFO Sean A. Power sold 32,006 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the sale, the chief financial officer now owns 517,464 shares in the company, valued at $4,398,444. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.70% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This piece was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2018/02/15/equities-analysts-set-expectations-for-tg-therapeutics-incs-fy2018-earnings-tgtx.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.